Home World News FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients... World News FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 896 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 June 24, 2021 ESMO Welcomes European Parliament Resolution Marking World Cancer Day February 11, 2026 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 Load more HOT NEWS Increased Risk of Cancer in Early Life Among Individuals with Autism... Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives
